Antimicrobial Peptide, Lumbricusin, Ameliorates Motor Dysfunction and Dopaminergic Neurodegeneration in a Mouse Model of Parkinson’s Disease
2
조회
0
다운로드
5
인용
0
참고문헌
키워드
초록
We recently reported that the antimicrobial peptide Lumbricusin (NH2-RNRRWCIDQQA), isolated from the earthworm, increases cell proliferation in neuroblastoma SH-SY5Y cells. Here, we investigated whether Lumbricusin has neurotropic activity in mouse neural stem cells (MNSCs) and a protective effect in a mouse model of Parkinson’s disease (PD). In MNSCs isolated from mouse brains, Lumbricusin treatment significantly increased cell proliferation (up to 12%) and reduced the protein expression of p27Kip1 through proteasomal protein degradation but not transcriptional regulation. Lumbricusin inhibited the 6-OHDA-induced apoptosis of MNSCs, and also showed neuroprotective effects in a mouse PD model, ameliorating the motor impairments seen in the pole, elevated body swing, and rotation tests. These results suggest that the Lumbricusin-induced promotion of neural cell proliferation via p27Kip1 degradation has a protective effect in an experimental PD model. Thus, the antimicrobial peptide Lumbricusin could possibly be developed as a potential therapeutic agent for the treatment of PD.
Abstract
We recently reported that the antimicrobial peptide Lumbricusin (NH2-RNRRWCIDQQA), isolated from the earthworm, increases cell proliferation in neuroblastoma SH-SY5Y cells. Here, we investigated whether Lumbricusin has neurotropic activity in mouse neural stem cells (MNSCs) and a protective effect in a mouse model of Parkinson’s disease (PD). In MNSCs isolated from mouse brains, Lumbricusin treatment significantly increased cell proliferation (up to 12%) and reduced the protein expression of p27Kip1 through proteasomal protein degradation but not transcriptional regulation. Lumbricusin inhibited the 6-OHDA-induced apoptosis of MNSCs, and also showed neuroprotective effects in a mouse PD model, ameliorating the motor impairments seen in the pole, elevated body swing, and rotation tests. These results suggest that the Lumbricusin-induced promotion of neural cell proliferation via p27Kip1 degradation has a protective effect in an experimental PD model. Thus, the antimicrobial peptide Lumbricusin could possibly be developed as a potential therapeutic agent for the treatment of PD.
참고문헌 (32)
- Chaudhry IB, "Minocycline benefits negative symptoms in early schizophrenia: a randomised doubleblind placebo-controlled clinical trial in patients on standard treatment", J. Psychopharmacol, 26, pp.1185~1193 (2012)
- Chen LW, "Neurokinin peptides and neurokinin receptors as potential therapeutic intervention targets of basal ganglia in the prevention and treatment of Parkinson’s disease", Curr. Drug Targets, 5, pp.197~206 (2004)
- da Rocha MD, "The role of natural products in the discovery of new drug candidates for the treatment of neurodegenerative disorders II: Alzheimer's disease", CNS Neurol. Disord. Drug Targets, 10, pp.251~270 (2011)
- Dixit A, "Minocycline, levodopa and MnTMPyP induced changes in the mitochondrial proteome profile of MPTP and maneb and paraquat mice models of Parkinson's disease", Biochim. Biophys. Acta, 1832, pp.1227~1240 (2013)
- Eggert A, "Molecular dissection of TrkA signal transduction pathways mediating differentiation in human neuroblastoma cells", Oncogene, 19, pp.2043~2051 (2000)
- Garcia C, "Symptom-relieving and neuroprotective effects of the phytocannabinoid delta(9)-THCV in animal models of Parkinson’s disease", Br. J. Pharmacol, 163, pp.1495~1506 (2011)
- Gupta A, "Targeting oxidative stress, mitochondrial dysfunction and neuroinflammatory signaling by selective cyclooxygenase (COX)-2 inhibitors mitigates MPTP-induced neurotoxicity in mice", Prog. Neuropsychopharmacol. Biol. Psychiatry, 35, pp.974~981 (2011)
- Hoehn MM, "Parkinsonism: onset, progression and mortality", Neurology, 17, pp.427~442 (1967)
- Hwang DY, "3,4-Dihydroxyphenylalanine reverses the motor deficits in Pitx3-deficient aphakia mice:behavioral characterization of a novel genetic model of Parkinson's disease", J. Neurosci, 25, pp.2132~2137 (2005)
- Bo Ram Kang, "CopA3 peptide from Copris tripartitus induces apoptosis in human leukemia cells via a caspase-independent pathway", BMB Reports, 45(2), pp.85~90 (2012), 생화학분자생물학회
- Kang JK, "Downregulation of erythropoietin receptor by overexpression of phospholipase C-gamma 1 is critical for decrease on focal adhesion in transformed cells", Cell. Oncol. (Dordr), 34, pp.11~21 (2011)
- Kang JK, "The insect peptide coprisin prevents Clostridium difficile-mediated acute inflammation and mucosal damage through selective antimicrobial activity", Antimicrob. Agents Chemother, 55, pp.4850~4857 (2011)
- Kim DH, "Neurotropic and neuroprotective activities of the earthworm peptide Lumbricusin", Biochem. Biophys. Res. Commun, 448, pp.292~297 (2014)
- Kim H, "Clostridium difficile toxin Ainduced colonocyte apoptosis involves p53-dependent p21(WAF1", CIP1) induction via p38 mitogen-activated protein kinase, 2005, pp.129, 1875~1888
- Kim H, "Clostridium difficile toxin A regulates inducible cyclooxygenase-2 and prostaglandin E2 synthesis in colonocytes via reactive oxygen species and activation of p38 MAPK", J. Biol. Chem, 280, pp.21237~21245 (2005)
- Kwon SH, "Lonicera japonica THUNB. protects 6-hydroxydopamine-induced neurotoxicity by inhibiting activation of MAPKs, PI3K", Akt, and NF-kappaB in SH-SY5Y cells, 2012, pp.50, 797~807
- Laganiere J, "An engineered zinc finger protein activator of the endogenous glial cell line-derived neurotrophic factor gene provides functional neuroprotection in a rat model of Parkinson’s disease", J. Neurosci, 30, pp.16469~16474 (2010)
- Li Y, "Knockdown of glycogen synthase kinase 3 beta attenuates 6-hydroxydopamineinduced apoptosis in SH-SY5Y cells", Neurosci. Lett, 487, pp.41~46 (2011)
- Lin CJ, "Ergonomic investigation of weight distribution of laparoscopic instruments", J. Laparoendosc. Adv. Surg. Tech. A, 21, pp.411~415 (2011)
- Litteljohn D, "Inflammatory mechanisms of neurodegeneration in toxin-based models of Parkinson’s disease", Parkinsons Dis, 2011, pp.713517~ (2010)
- dopa PET, "J. Neurol. Neurosurg. Psychiatry", 1998, 314~319
- Munoz U, "Enhanced proteasome-dependent degradation of the CDK inhibitor p27(kip1) in immortalized lymphocytes from Alzheimer’s dementia patients", Neurobiol. Aging, 29, pp.1474~1484 (2008)
- Nam HJ, "The insect peptide CopA3 inhibits lipopolysaccharideinduced macrophage activation", J. Pept. Sci, 18, pp.650~656 (2012)
- Nam ST, "Insect peptide CopA3-induced protein degradation of p27Kip1 stimulates proliferation and protects neuronal cells from apoptosis", Biochem. Biophys. Res. Commun, 437, pp.35~40 (2013)
- Ohta M, "Apomorphine up-regulates NGF and GDNF synthesis in cultured mouse astrocytes", Biochem. Biophys. Res. Commun, 272, pp.18~22 (2000)
- Qiu J, "p27Kip1 constrains proliferation of neural progenitor cells in adult brain under homeostatic and ischemic conditions", Stem Cells, 27, pp.920~927 (2009)
- Rangasamy SB, "Neurotrophic factor therapy for Parkinson’s disease", Prog. Brain Res, 184, pp.237~264 (2010)
- Rothstein JD, "Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression", Nature, 433, pp.73~77 (2005)
- Sharma NK, "Activity-dependent neuroprotective protein (ADNP)-derived peptide (NAP) ameliorates hypobaric hypoxia induced oxidative stress in rat brain", Peptides, 32, pp.1217~1224 (2011)
- Vercammen L, "Parkin protects against neurotoxicity in the 6-hydroxydopamine rat model for Parkinson’s disease", Mol. Ther, 14, pp.716~723 (2006)
- Wallen A, "Transcriptional control of dopamine neuron development", Ann. NY Acad. Sci, 991, pp.48~60 (2003)
- Yoo J, "Effects of stromal cell-derived factor 1alpha delivered at different phases of transient focal ischemia in rats", Neuroscience, 209, pp.171~186 (2012)